{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:53:15Z","timestamp":1779367995661,"version":"3.53.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009098","name":"Japanese Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.resinv.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T23:27:02Z","timestamp":1727306822000},"page":"1079-1087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"62","author":[{"given":"Natsuki","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9498-6995","authenticated-orcid":false,"given":"Masashi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3122-6937","authenticated-orcid":false,"given":"Takanori","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Obase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.resinv.2024.09.004_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.resinv.2024.09.004_bib3","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.chest.2018.07.014","article-title":"Characteristics and health-care utilization history of patients with bronchiectasis in US medicare enrollees with prescription drug plans, 2006 to 2014","volume":"154","author":"Henkle","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00424-2022","article-title":"Epidemiological characteristics of nontuberculous mycobacteriosis and bronchiectasis: comparative study using national mortality statistics from 1970 to 2015 in Japan","volume":"9","author":"Morimoto","year":"2023","journal-title":"ERJ Open Res"},{"issue":"10150","key":"10.1016\/j.resinv.2024.09.004_bib5","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.resinv.2024.09.004_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \"frequent exacerbator phenotype\" in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.resinv.2024.09.004_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00408-014-9619-0","article-title":"Low-dose clarithromycin therapy modulates Th17 response in non-cystic fibrosis bronchiectasis patients","volume":"192","author":"Fouka","year":"2014","journal-title":"Lung"},{"key":"10.1016\/j.resinv.2024.09.004_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/708608","article-title":"Effect of low-dose, long-term roxithromycin on airway inflammation and remodeling of stable noncystic fibrosis bronchiectasis","volume":"2014","author":"Liu","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"10","key":"10.1016\/j.resinv.2024.09.004_bib9","first-page":"1697","article-title":"Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low-dose erythromycin study trial","volume":"13","author":"Burr","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.resinv.2024.09.004_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/000348949710600813","article-title":"Effects of indomethacin, dexamethasone, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium","volume":"106","author":"Takahashi","year":"1997","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"10","key":"10.1016\/j.resinv.2024.09.004_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.resinv.2024.09.004_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib13","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"5","author":"Hill","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"9842","key":"10.1016\/j.resinv.2024.09.004_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.resinv.2024.09.004_bib15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.resinv.2024.09.004_bib16","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S2213-2600(14)70213-9","article-title":"The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial","volume":"2","author":"Rogers","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.resinv.2024.09.004_bib17","first-page":"Cd012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"17","key":"10.1016\/j.resinv.2024.09.004_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015285","article-title":"Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis","volume":"98","author":"Wang","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"7","key":"10.1016\/j.resinv.2024.09.004_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.resinv.2024.09.004_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arbres.2017.07.015","article-title":"Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00611-2022","article-title":"Clinical outcomes of bronchiectasis in India: data from the EMBARC\/Respiratory Research Network of India registry","volume":"61","author":"Dhar","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.09.004_bib22","series-title":"Cochrane handbook for systematic reviews of interventions version 5.0. 1","author":"Higgins","year":"2008"},{"issue":"4","key":"10.1016\/j.resinv.2024.09.004_bib23","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"issue":"2","key":"10.1016\/j.resinv.2024.09.004_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00151829-200504020-00005","article-title":"The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis","volume":"4","author":"Cymbala","year":"2005","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.resinv.2024.09.004_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106718","article-title":"The effect of maintenance azithromycin on radiological features in patients with bronchiectasis - analysis from the BAT randomized controlled trial","volume":"192","author":"Terpstra","year":"2022","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.resinv.2024.09.004_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.rmed.2011.01.009","article-title":"Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations","volume":"105","author":"Serisier","year":"2011","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.resinv.2024.09.004_bib28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/resp.12375","article-title":"Efficacy of azithromycin in the treatment of bronchiectasis","volume":"19","author":"Lourdesamy Anthony","year":"2014","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.resinv.2024.09.004_bib29","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/resp.12130","article-title":"Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis","volume":"18","author":"Diego","year":"2013","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.resinv.2024.09.004_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00103-18","article-title":"Impact of long-term erythromycin therapy on the oropharyngeal microbiome and resistance gene reservoir in non-cystic fibrosis bronchiectasis","volume":"3","author":"Choo","year":"2018","journal-title":"mSphere"},{"issue":"12","key":"10.1016\/j.resinv.2024.09.004_bib31","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.2013.2290","article-title":"Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial","volume":"309","author":"Serisier","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.resinv.2024.09.004_bib32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1183\/09031936.99.13236199","article-title":"A pilot study of low-dose erythromycin in bronchiectasis","volume":"13","author":"Tsang","year":"1999","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.resinv.2024.09.004_bib33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/resp.12233","article-title":"Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis","volume":"19","author":"Wu","year":"2014","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pupt.2014.02.002","article-title":"Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials","volume":"29","author":"Zhuo","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03778-8","article-title":"Long-term macrolide treatment for non-cystic fibrosis bronchiectasis in children: a meta-analysis","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.resinv.2024.09.004_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090047","article-title":"Macrolide therapy in adults and children with non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis","volume":"9","author":"Gao","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.resinv.2024.09.004_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pupt.2013.09.003","article-title":"Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review","volume":"28","author":"Shi","year":"2014","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13019-022-01882-y","article-title":"The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies","volume":"17","author":"Li","year":"2022","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.resinv.2024.09.004_bib39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12879-015-0872-5","article-title":"Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials","volume":"15","author":"Fan","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib40","doi-asserted-by":"crossref","first-page":"9168","DOI":"10.1038\/s41598-017-06862-0","article-title":"Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India","volume":"7","author":"Parker","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.resinv.2024.09.004_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-199920010-00004","article-title":"Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients","volume":"20","author":"Principi","year":"1999","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.resinv.2024.09.004_bib42","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.resinv.2024.09.004_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170622","article-title":"Longitudinal assessment of sputum microbiome by sequencing of the 16S rRNA gene in non-cystic fibrosis bronchiectasis patients","volume":"12","author":"Cox","year":"2017","journal-title":"PLoS One"}],"updated-by":[{"DOI":"10.1016\/j.resinv.2025.01.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T08:52:00Z","timestamp":1732092720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2212534524001436"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.09.004","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.resinv.2025.01.002","asserted-by":"object"}]},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of long-term macrolide therapy for non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}